GILD NASDAQ
Gilead Sciences, Inc.
1W: +1.6%
1M: +4.5%
3M: +19.9%
YTD: +30.8%
1Y: +32.4%
3Y: +120.8%
5Y: +179.1%
$159.08
+0.39 (+0.25%)
Weekly Expected Move ±4.0%
$144
$150
$156
$162
$169
Credit Risk of going bust: lower than 84% of companies Debt: 11.7% of company value Bonds: $407.1M held by 325 funds, 58 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.38 (down 99.1%), Gilead Sciences, Inc. would be worth roughly what it owes.
Total debt $26.25B against a stock market value of $197.25B.
Distance to default 10.80 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $14.33B (short-term plus half of long-term), stock volatility 26.8%; Altman Z 3.80. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.38 (down 99.1%), Gilead Sciences, Inc. would be worth roughly what it owes.
Total debt $26.25B against a stock market value of $197.25B.
Distance to default 10.80 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $14.33B (short-term plus half of long-term), stock volatility 26.8%; Altman Z 3.80. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.30
Neutral
1 bullish
2 neutral
0 bearish
Articles (24h)
3
Hourly Sentiment (24h)
0.22
Neutral
6 bullish
8 neutral
2 bearish
Articles (7d)
16
Daily Sentiment (7 Days)
Articles (100)
Gilead to Report Q3 Earnings: How Should You Play the Stock Now?
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?
BHC Q3 Earnings Preview: Here's What You Should Know
TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Gilead Sciences, Inc. $GILD Stock: Citizens Financial Group Inc. RI Increases Stake
Earnings Week Ahead: MSFT, GOOGL, AMZN, XOM, BA, VZ, and more
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?
Gilead in $45M settlement with Texas over alleged Medicaid kickback scheme
BioNTech to investigate pumitamig in combination with Gilead's Trodelvy
Gilead acquires oral IL-23R inhibitor program from PepStar for ~$1.3B
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note
XLV touches a new high, hitting overbought territory
15,240 Gilead Sciences, Inc. $GILD Shares Bought by CWA Asset Management Group LLC
Quality stocks breaking out as mid-cycle shift accelerates - Morgan Stanley
All You Need to Know About Gilead (GILD) Rating Upgrade to Buy
Gilead hits mid-stage trial success for oral bowel disease therapy
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
ClearBridge Value Strategy adds eight stocks, and exits 10 positions in Q3
Vir jumps on Gilead licensing deal worth up to $1.9B for cancer drugs
Gilead Sciences, Inc. $GILD Stock Acquired by RHS Financial LLC
44,466 Gilead Sciences, Inc. $GILD Shares Sold by CoreCap Advisors LLC
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Gilead Sciences (GILD) Laps the Stock Market: Here's Why
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
U.S. equities tumble while Treasury yields push higher
12,110 Gilead Sciences, Inc. $GILD Shares Sold by CapWealth Advisors LLC
31,384 Gilead Sciences, Inc. $GILD Shares Sold by CX Institutional
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Medicare drug pricing model to affect only four firms after Trump’s MFN policy
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
Pharmaceutical industry lobbying group names new CEO, Eric Cantor
Gilead Sciences, Inc. $GILD Stake Decreased by Envestnet Asset Management Inc.
Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
Healthcare stocks with the strongest dividend growth grades
J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?
Trump administration is said to weigh allowing most pharma licensing deals with China
Looming biosimilar void risks $189B in lost U.S. healthcare savings: report
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America
Gilead expands voluntary licensing agreements for once-yearly Yeztugo
FDA launches pilot program that aims to speed the time to first-in-human drug trials
Bank of America Corp DE Sells 1,329,871 Shares of Gilead Sciences, Inc. $GILD
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Baird Financial Group Inc. Grows Holdings in Gilead Sciences, Inc. $GILD
Here's Why You Should Add NRIX Stock to Your Portfolio Now
Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?
FDA names acting heads of drug and vaccine units to permanent roles
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights
California State Teachers Retirement System Has $30.47 Billion Stake in Gilead Sciences, Inc. $GILD
Compass Financial Management LLC Invests $671,000 in Gilead Sciences, Inc. $GILD
HB Wealth Management LLC Decreases Stake in Gilead Sciences, Inc. $GILD
Gilead Sciences, Inc. $GILD Shares Bought by Concurrent Investment Advisors LLC
5,212 Shares in Gilead Sciences, Inc. $GILD Bought by AlphaGrep UK Ltd
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?
Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?
Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?
Top Research Reports for Toyota Motor, CrowdStrike & Welltower
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock?
Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?
Archer Investment Corp Takes Position in Gilead Sciences, Inc. $GILD
BNP Paribas Purchases 20,329 Shares of Gilead Sciences, Inc. $GILD
Beacon Pointe Advisors LLC Reduces Holdings in Gilead Sciences, Inc. $GILD
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection
Bamco Inc. NY Sells 12,000 Shares of Gilead Sciences, Inc. $GILD
Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting
EC Approves Label Expansion of GILD's Trodelvy in First-line Metastatic TNBC
3 Dividend Stocks to Hold for the Next 10 Years
Bristol Myers reportedly exits Cellares pact prompting restructuring at cell therapy maker
Advisors Capital Management LLC Takes Position in Gilead Sciences, Inc. $GILD
Allworth Financial LP Invests $5.96 Million in Gilead Sciences, Inc. $GILD
59,974 Shares in Gilead Sciences, Inc. $GILD Purchased by Abacus FCF Advisors LLC
Trump nominates White House adviser Overton as next FDA commissioner
Worried About a Market Crash? These 3 Stocks Beat the S&P 500 in 2008 and 2022
Aljian Capital Management LLC Invests $568,000 in Gilead Sciences, Inc. $GILD
Trump expected to nominate White House aide Heidi Overton as FDA commissioner
Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.
Capital Financial Group Inc. Co. ADV Invests $582,000 in Gilead Sciences, Inc. $GILD
AMG National Trust Bank Purchases Shares of 26,675 Gilead Sciences, Inc. $GILD
442,000 Shares in Gilead Sciences, Inc. $GILD Acquired by Alberta Investment Management Corp
BIP Wealth LLC Purchases New Holdings in Gilead Sciences, Inc. $GILD
Abundance Wealth Counselors Grows Stake in Gilead Sciences, Inc. $GILD
Benjamin Edwards Inc. Has $15.86 Million Stock Holdings in Gilead Sciences, Inc. $GILD
J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?
First Bank & Trust Lowers Stock Position in Gilead Sciences, Inc. $GILD
GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised
Compared to Estimates, Gilead (GILD) Q2 Earnings: A Look at Key Metrics